Beyang Raises $30 Million for AI-Designed Medicines
Chengdu-based Beyang Therapeutics closed an oversubscribed Series A of nearly $30 million, co-led by Legend Capital and Shanghai Healthcare Capital. Proceeds will support the ExCEED AI/molecular-design platform, clinical and preclinical programs and international development….
